KEDI Global Obesity Care Industry Top 2+ Index

Q2 2026 earnings release is expected.

Analysts estimate the next quarterly earnings report for Q2 2026 will occur on 2026-08-25. Given historical volatility, a price impact of at least 5% is expected.

Q2 2026 earnings release and conference call on August 5, 2026; low impact is estimated as the announcement is a routine scheduling event, scheduled.

Financial results for the first half of 2026, with importance estimated as Low based on typical market reaction to routine earnings dates, scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; a high impact is estimated as quarterly earnings typically drive significant volatility, scheduled.

Q2 2026 earnings release and conference call scheduled. Earnings announcements typically trigger price movements of 5% or more, justifying a medium importance estimate scheduled.

Q2 2026 earnings results to be released before market open on 2026-07-30, with a conference call at 10:00 a.m. ET. Medium importance is estimated as earnings typically drive significant price action, scheduled.

H1 and Q2 2026 earnings results scheduled to be released. A low impact is estimated as this is a routine financial disclosure scheduled.

Novartis is scheduled to announce its financial results for the second quarter of 2026, scheduled.

The US FDA granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). This converts the drug's 2024 accelerated approval to a full approval.

Truist Securities downgraded Lululemon stock from 'Hold' to 'Sell' and lowered its price target to $94 from $115 on July 16, 2026, citing weakening consumer trends; a price impact of over 10% is estimated.

Abbott reported Q2 2026 adjusted EPS of $1.31, beating estimates of ~$1.28, and raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. This guidance raise is estimated to cause a 5-9% price impact expected.

Wells Fargo analyst maintained an 'Overweight' rating and raised the price target on LTH to $46.00 from $38.00 on 2026-07-16, forecasted.

Positive results from the Phase 3 KEYNOTE-C93 trial for Keytruda in dMMR endometrial cancer patients are expected. High impact (>10%) estimated due to significant market expansion expected.

The ex-dividend date for a quarterly cash dividend of $0.63 per share is July 15, 2026. Routine dividends typically have a price impact of 1-4% scheduled.

The European Commission (EC) approved the once-daily oral version of Wegovy and a higher dose injection pen on July 15, 2026, resulting in a 3% stock price increase.

Announced an exclusive license agreement with Dizal Pharmaceutical to acquire worldwide rights to Zegfrovy, an oral lung cancer therapy. The deal includes a $600 million upfront payment and up to $900 million in milestones.